Point72 Asset Management
ZNTL icon

Point72 Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Point72 Asset Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$222K Sell
94,854
-5,436
-5% -$14K ﹤0.01% 3480
2025
Q4 		$135K Buy
+100,290
New +$146K ﹤0.01% 3704

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Point72 Asset Management's ZNTL Position: Q1 2026 in Review

Point72 Asset Management reduced its Zentalis Pharmaceuticals (ZNTL) stake by 5.4% in Q1 2026, selling an estimated $14K and leaving 94,854 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #3480.

Point72 Asset Management first reported a position in ZNTL in Q4 2025 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Point72 Asset Management held 94,854 shares of Zentalis Pharmaceuticals worth $222K as of Q1 2026.
  • Point72 Asset Management sold 5,436 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $14K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3480 holding.
  • Point72 Asset Management first reported a position in Zentalis Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.